Gemtuzumab ozogamicin

Gentuzumabe ozogamicinaGemtuzumab ozogamicina

None of the guidelines names a specific antidote or compress for this drug. See the general recommendations.

References

Risk class: IrritantJSCN/JSMO/JASPO 2024 (Table 2)

Not classified in: ONS/ASCO 2025, ESMO-EONS 2012

Not classified in: ONS/ASCO 2025, ESMO-EONS 2012

Brand names (ANVISA, Brazil) · DCB (Brazil)

DCB (Brazil)gentuzumabe ozogamicina (nº 9448)

Brand names (ANVISA, Brazil)MYLOTARG

General recommendations of the guidelines

ONS/ASCO 2025Recommendation 1 · Strong; very low
Use antidotes, when one exists, for vesicants and irritants with vesicant properties, rather than no antidote.
Table 3, p. 388
ONS/ASCO 2025Recommendation 3 · Conditional; very low
Thermal compress (cold or warm depending on the agent) rather than no compress.
Table 3, p. 388
ONS/ASCO 2025Recommendation 4 · Conditional; very low
Compress for more than 24 hours rather than 24 hours or less.
Table 3, p. 388
ONS/ASCO 2025Recommendation 5 · Conditional; very low
Central line extravasation: surgical referral or escalation of care in addition to conservative management.
Table 3, p. 388
JSCN/JSMO/JASPO 2024CQ10a · Recommend (weak)
Cold compression (weak recommendation).
Table 1, CQ10a
JSCN/JSMO/JASPO 2024CQ10b · Not recommend (weak); D
Non-use of warm compresses (weak recommendation).
Table 1, CQ10b